GENB
Generate Biomedicines, Inc.
Price Chart
Latest Quote
$15.43
-0.46 (-2.89%)
Current Price
| Previous Close | $15.89 |
| Open | $15.44 |
| Day High | $15.79 |
| Day Low | $14.99 |
| Volume | 831,411 |
Stock Information
| Shares Outstanding | 128.19M |
| Total Debt | $65.57M |
| Cash Equivalents | $516.64M |
| Revenue | $30.30M |
| Net Income | $-265.44M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.98B |
| EPS (TTM) | $-2.01 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.53B |
| Sales | $30.30M |
| Income | $-265.44M |
| Book/sh | $4.02 |
| Cash/sh | $4.03 |
| Employees | 312 |
Financial Ratios
| Quick Ratio | 8.85 |
| Current Ratio | 9.17 |
| Debt/Eq | 12.74 |
Returns & Margins
| Operating Margin | -887.49% |
Ownership
| Insider Ownership | 14.07% |
| Institutional Ownership | 72.00% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -7.47 |
| P/S | 65.28 |
| P/B | 3.84 |
Analyst Data
| Recommendation | none |
| Target Price | $25.40 |
Technical Indicators
| SMA20 | $13.46 |
| SMA50 | $13.52 |
| RSI | 66.86 |
| ATR | 1.1471 |
| Shares Float | 60.29M |
| Short Float | 5.48% |
| Short Ratio | 7.08 |
| Rel Volume | 0.87 |
Performance History
| Week | +13.62% |
| Month | +10.37% |
| Quarter | +23.24% |
| YTD | +21.98% |
| 10 Years | +21.98% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $15.43 | 831,411 |
| 2026-06-22 | $15.89 | 1,250,600 |
| 2026-06-18 | $14.49 | 2,604,800 |
| 2026-06-17 | $13.87 | 802,100 |
| 2026-06-16 | $13.37 | 631,800 |
| 2026-06-15 | $13.58 | 619,000 |
| 2026-06-12 | $12.38 | 688,500 |
| 2026-06-11 | $12.93 | 511,600 |
| 2026-06-10 | $13.16 | 382,500 |
| 2026-06-09 | $13.19 | 615,500 |
| 2026-06-08 | $12.78 | 817,200 |
| 2026-06-05 | $12.87 | 1,637,200 |
| 2026-06-04 | $14.70 | 2,513,000 |
| 2026-06-03 | $12.91 | 762,300 |
| 2026-06-02 | $11.97 | 1,223,300 |
| 2026-06-01 | $12.97 | 679,000 |
| 2026-05-29 | $13.12 | 441,100 |
| 2026-05-28 | $13.09 | 454,000 |
| 2026-05-27 | $13.08 | 598,800 |
| 2026-05-26 | $13.34 | 1,038,700 |
About Generate Biomedicines, Inc.
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.
đ° Latest News
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB)
Insider Monkey âĸ 2026-06-23T19:39:22Z
A Look At Generate Biomedicines (GENB) Valuation As Shares Soften After Recent Gains
Simply Wall St. âĸ 2026-06-01T19:07:09Z
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer
Motley Fool âĸ 2026-05-31T20:37:57Z
A Deep Dive Into NVIDIAâs Latest Portfolio Moves
MarketBeat âĸ 2026-05-19T18:05:00Z
H.C. Wainwright Initiates Coverage of Generate Biomedicines (GENB) With a Buy Rating
Insider Monkey âĸ 2026-04-20T00:11:46Z
Generate Biomedicines (GENB) Valuation Check After Recent Share Price Weakness
Simply Wall St. âĸ 2026-03-08T09:11:48Z
Sector Update: Health Care Stocks Advance Late Afternoon
MT Newswires âĸ 2026-02-27T21:02:29Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $31,893,000 | $20,459,000 |
| Operating Revenue | $31,893,000 | $20,459,000 |
| Expenses | ||
| Interest Expense | $1,136,000 | $2,118,000 |
| Total Expenses | $266,958,000 | $217,398,000 |
| Other Income Expense | $-262,000 | $-233,000 |
| Net Non Operating Interest Income Expense | $12,525,000 | $16,000,000 |
| Interest Expense Non Operating | $1,136,000 | $2,118,000 |
| Operating Expense | $266,958,000 | $217,398,000 |
| General And Administrative Expense | $42,260,000 | $42,087,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-203,154,000 | $-173,771,000 |
| Net Interest Income | $12,525,000 | $16,000,000 |
| Interest Income | $13,661,000 | $18,118,000 |
| Normalized Income | $-202,947,020 | $-173,586,930 |
| Net Income From Continuing And Discontinued Operation | $-203,154,000 | $-173,771,000 |
| Total Operating Income As Reported | $-235,065,000 | $-196,939,000 |
| Net Income Common Stockholders | $-249,523,000 | $-213,777,000 |
| Net Income | $-203,154,000 | $-173,771,000 |
| Net Income Including Noncontrolling Interests | $-222,965,000 | $-181,384,000 |
| Net Income Continuous Operations | $-222,965,000 | $-181,384,000 |
| Pretax Income | $-222,802,000 | $-181,172,000 |
| Interest Income Non Operating | $13,661,000 | $18,118,000 |
| Operating Income | $-235,065,000 | $-196,939,000 |
| Per Share | ||
| Diluted EPS | $-2.18 | $-2.09 |
| Basic EPS | $-2.18 | $-2.09 |
| Other | ||
| Tax Effect Of Unusual Items | $-55,020 | $-48,930 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-208,226,000 | $-163,472,000 |
| Total Unusual Items | $-262,000 | $-233,000 |
| Total Unusual Items Excluding Goodwill | $-262,000 | $-233,000 |
| Reconciled Depreciation | $13,178,000 | $15,349,000 |
| EBITDA (Bullshit earnings) | $-208,488,000 | $-163,705,000 |
| EBIT | $-221,666,000 | $-179,054,000 |
| Diluted Average Shares | $102,307,938 | $102,307,938 |
| Basic Average Shares | $102,307,938 | $102,307,938 |
| Diluted NI Availto Com Stockholders | $-249,523,000 | $-213,777,000 |
| Preferred Stock Dividends | $46,369,000 | $40,006,000 |
| Minority Interests | $19,811,000 | $7,613,000 |
| Tax Provision | $163,000 | $212,000 |
| Gain On Sale Of Security | $-262,000 | $-233,000 |
| Research And Development | $224,698,000 | $175,311,000 |
| Selling General And Administration | $42,260,000 | $42,087,000 |
| Other Gand A | $14,172,000 | $14,222,000 |
| Salaries And Wages | $28,088,000 | $27,865,000 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-615,965,000 | $-434,519,000 |
| Total Assets | $330,182,000 | $518,259,000 |
| Total Non Current Assets | $95,817,000 | $110,768,000 |
| Other Non Current Assets | $6,806,000 | $9,700,000 |
| Current Assets | $234,365,000 | $407,491,000 |
| Other Current Assets | $12,528,000 | $12,129,000 |
| Restricted Cash | $339,000 | $1,427,000 |
| Receivables | $0 | $308,000 |
| Accounts Receivable | $0 | $308,000 |
| Cash Cash Equivalents And Short Term Investments | $221,498,000 | $393,627,000 |
| Cash And Cash Equivalents | $121,650,000 | $176,269,000 |
| Debt | ||
| Total Debt | $68,526,000 | $76,972,000 |
| Long Term Debt And Capital Lease Obligation | $53,518,000 | $60,255,000 |
| Current Debt And Capital Lease Obligation | $15,008,000 | $16,717,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $953,379,000 | $953,349,000 |
| Total Non Current Liabilities Net Minority Interest | $871,176,000 | $866,723,000 |
| Other Non Current Liabilities | $116,000 | $349,000 |
| Derivative Product Liabilities | $1,205,000 | $1,092,000 |
| Non Current Deferred Liabilities | $4,511,000 | $15,174,000 |
| Current Liabilities | $82,203,000 | $86,626,000 |
| Other Current Liabilities | $2,628,000 | $2,432,000 |
| Current Deferred Liabilities | $21,194,000 | $42,425,000 |
| Payables And Accrued Expenses | $29,575,000 | $11,701,000 |
| Payables | $3,837,000 | $5,667,000 |
| Accounts Payable | $3,837,000 | $5,667,000 |
| Equity | ||
| Common Stock Equity | $-615,965,000 | $-434,519,000 |
| Total Equity Gross Minority Interest | $-623,197,000 | $-435,090,000 |
| Stockholders Equity | $-615,965,000 | $-434,519,000 |
| Gains Losses Not Affecting Retained Earnings | $106,000 | $118,000 |
| Other Equity Adjustments | $106,000 | $118,000 |
| Retained Earnings | $-676,293,000 | $-473,139,000 |
| Preferred Securities Outside Stock Equity | $811,826,000 | $789,853,000 |
| Other | ||
| Ordinary Shares Number | $127,450,201 | $127,450,201 |
| Share Issued | $127,450,201 | $127,450,201 |
| Tangible Book Value | $-615,965,000 | $-434,519,000 |
| Invested Capital | $-615,965,000 | $-434,519,000 |
| Working Capital | $152,162,000 | $320,865,000 |
| Capital Lease Obligations | $68,526,000 | $76,972,000 |
| Total Capitalization | $-615,965,000 | $-434,519,000 |
| Minority Interest | $-7,232,000 | $-571,000 |
| Additional Paid In Capital | $60,189,000 | $38,469,000 |
| Capital Stock | $33,000 | $33,000 |
| Common Stock | $33,000 | $33,000 |
| Non Current Deferred Revenue | $4,511,000 | $15,174,000 |
| Long Term Capital Lease Obligation | $53,518,000 | $60,255,000 |
| Current Deferred Revenue | $21,194,000 | $42,425,000 |
| Current Capital Lease Obligation | $15,008,000 | $16,717,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $13,798,000 | $13,351,000 |
| Current Accrued Expenses | $25,738,000 | $6,034,000 |
| Net PPE | $89,011,000 | $101,068,000 |
| Accumulated Depreciation | $-48,257,000 | $-35,172,000 |
| Gross PPE | $137,268,000 | $136,240,000 |
| Leases | $9,661,000 | $9,626,000 |
| Construction In Progress | $4,105,000 | $886,000 |
| Other Properties | $117,966,000 | $120,248,000 |
| Machinery Furniture Equipment | $5,536,000 | $5,480,000 |
| Properties | $0 | $0 |
| Other Short Term Investments | $99,848,000 | $217,358,000 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-204,133,000 | $-121,197,000 |
| Operating Activities | ||
| Operating Cash Flow | $-200,619,000 | $-117,750,000 |
| Cash Flow From Continuing Operating Activities | $-200,619,000 | $-117,750,000 |
| Operating Gains Losses | $49,000 | $144,000 |
| Investing Activities | ||
| Capital Expenditure | $-3,514,000 | $-3,447,000 |
| Investing Cash Flow | $116,767,000 | $-57,725,000 |
| Cash Flow From Continuing Investing Activities | $116,767,000 | $-57,725,000 |
| Financing Activities | ||
| Issuance Of Capital Stock | $21,973,000 | $96,324,000 |
| Financing Cash Flow | $28,059,000 | $91,327,000 |
| Cash Flow From Continuing Financing Activities | $28,059,000 | $91,327,000 |
| Net Other Financing Charges | $13,150,000 | $5,000,000 |
| Net Preferred Stock Issuance | $21,973,000 | $96,324,000 |
| Preferred Stock Issuance | $21,973,000 | $96,324,000 |
| Other | ||
| Repayment Of Debt | $-8,161,000 | $-11,124,000 |
| End Cash Position | $126,038,000 | $181,831,000 |
| Beginning Cash Position | $181,831,000 | $265,979,000 |
| Changes In Cash | $-55,793,000 | $-84,148,000 |
| Proceeds From Stock Option Exercised | $1,097,000 | $1,127,000 |
| Net Issuance Payments Of Debt | $-8,161,000 | $-11,124,000 |
| Net Long Term Debt Issuance | $-8,161,000 | $-11,124,000 |
| Long Term Debt Payments | $-8,161,000 | $-11,124,000 |
| Net Investment Purchase And Sale | $120,281,000 | $-54,288,000 |
| Sale Of Investment | $285,012,000 | $228,691,000 |
| Purchase Of Investment | $-164,731,000 | $-282,979,000 |
| Net PPE Purchase And Sale | $-3,514,000 | $-3,437,000 |
| Sale Of PPE | $0 | $10,000 |
| Purchase Of PPE | $-3,514,000 | $-3,447,000 |
| Change In Working Capital | $-14,616,000 | $28,118,000 |
| Change In Other Working Capital | $-31,894,000 | $34,541,000 |
| Change In Other Current Liabilities | $-2,943,000 | $-5,201,000 |
| Change In Other Current Assets | $4,835,000 | $-3,499,000 |
| Change In Payables And Accrued Expense | $15,244,000 | $7,868,000 |
| Change In Accrued Expense | $17,374,000 | $4,369,000 |
| Change In Payable | $-2,130,000 | $3,499,000 |
| Change In Account Payable | $-2,130,000 | $3,499,000 |
| Change In Prepaid Assets | $-166,000 | $-5,378,000 |
| Change In Receivables | $308,000 | $-213,000 |
| Changes In Account Receivables | $308,000 | $-213,000 |
| Other Non Cash Items | $5,941,000 | $6,006,000 |
| Stock Based Compensation | $20,577,000 | $19,465,000 |
| Amortization Of Securities | $-2,783,000 | $-5,448,000 |
| Depreciation Amortization Depletion | $13,178,000 | $15,349,000 |
| Depreciation And Amortization | $13,178,000 | $15,349,000 |
| Gain Loss On Investment Securities | $113,000 | $154,000 |
| Gain Loss On Sale Of PPE | $-64,000 | $-10,000 |
| Net Income From Continuing Operations | $-222,965,000 | $-181,384,000 |
Fetched: 2026-06-22